IMATINIB RESISTANCE MUTATION ANALYSIS; IRMA

Test Usage:

Imatinib is a Tyrosine kinase inhibitor (TKI) capable of inducing durable hematologic and cytologic remissions in patients with Chronic Myeloid Leukemia (CML). Unfortunately a significant subset of patients develop functional resistance to TKI. Recognition of this resistance is important in CML as the effect of some mutations can be overcome by Imatinib dosage.